Table 1 Sample characteristics
Treatment preparation | IFNβ-1a i.m. | IFNβ-1a s.c. | IFNβ-1b s.c. | |||
|---|---|---|---|---|---|---|
Cohort | KI Sweden | TUM Germany | KI Sweden | TUM Germany | KI Sweden | TUM Germany |
N (%) | 345 (24.7) | 251 (18.4) | 590 (42.3) | 558 (40.9) | 459 (32.9) | 554 (40.6) |
Mean age (SD) | 46.7 (9.9) | 40.1 (9.6) | 44.1 (9.9) | 38.9 (9.6) | 45.4 (10.4) | 41.4 (10.4) |
Female sex (%) | 216 (62.6) | 191 (76.1) | 440 (74.6) | 406 (72.8) | 334 (72.8) | 390 (70.4) |
Median treatment duration in months (MAD) | 21.0 (8.1) | 40.0 (20.4) | 30.0 (15.0) | 55.2 (23.1) | 24.9 (12.9) | 46.9 (23.4) |
Progressive MS (%) | 60 (17.4) | 34 (13.5) | 120 (20.3) | 90 (16.1) | 130 (28.3) | 128 (23.1) |
nADA positive (%) | 45 (13.0) | 41 (16.3) | 204 (34.6) | 188 (33.7) | 245 (53.4) | 255 (46.0) |
Median nADA titer (MAD) nADA-positive samples | 320 (280) | 320 (280) | 640 (600) | 1280 (1240) | 320 (280) | 320 (280) |
Median bADA level (MAD) all samples | 13.9 (6.5) | 9.6 (5.7) | 23.2 (13.9) | 16.3 (10.5) | 35.8 (19.9) | 29.4 (20.0) |
Median bADA level (MAD) nADA-positive samples | 63.8 (42.6) | 25.8 (22.3) | 109.0 (84.8) | 115.0 (104.0) | 69.0 (37.0) | 73.8 (50.7) |